A common functional variant of endoplasmic reticulum aminopeptidase 2 (ERAP2) that reduces major histocompatibility complex class I expression is not associated with ankylosing spondylitis by Harvey, David et al.
Letters to the Editor
Rheumatology 2011;50:17201721
doi:10.1093/rheumatology/ker199
Advance Access publication 29 June 2011
A common functional variant of endoplasmic
reticulum aminopeptidase 2 (ERAP2) that reduces
major histocompatibility complex class I
expression is not associated with ankylosing
spondylitis
SIR, The strong genetic association between AS and
HLA-B27 has defied explanation for nearly 40 years.
However, the additional discovery of a strong association
between AS and ERAP1 (endoplasmic reticulum amino-
peptidase 1), a gene that almost certainly operates in the
trimming of peptides for optimal binding to MHC class I
molecules, has rekindled hopes of rapid advances in this
field [1]. It has been suggested that another aminopepti-
dase, endoplasmic reticulum aminopeptidase 2 (ERAP2),
may act in concert with ERAP1, trimming residues inef-
ficiently removed by ERAP1 [2]. The association desc-
ribed recently between ERAP2 and Crohn’s disease,
which shares many clinical and genetic overlaps with AS
[3], suggests that ERAP2 is worthy of further study in AS.
An experiment of nature allows us to do this relatively
simply.
ERAP2 has evolved under balancing selection, similar to
the MHC, and includes a high-frequency variant ( 50%)
that influences antigen presentation [4]. A single nucleo-
tide polymorphism (SNP), rs2248374 (A to G), located
within the 50 canonical splice site of exon 10, results in
an alternatively spliced ERAP2 mRNA that is degraded by
nonsense-mediated decay (NMD). Homozygosity for the
minor G allele (carried by  25% of the population) results
in failure to express ERAP2 protein; in turn this genotype
is also associated with reduced surface MHC Class I
expression on human B cells [4]. Such a dramatic pheno-
typic effect provides a great opportunity for studying
the potential role of ERAP2 in AS, analogous to using a
knockout model.
We therefore specifically tested for differences in fre-
quency of rs2248374 in 470 sporadic AS cases and
420 healthy, ethnically matched blood donors to deter-
mine whether this functionally important variant is impli-
cated in AS. All patients were Caucasians, of UK origin
and fulfilled the modified New York criteria for AS.
Eighty-four per cent of the AS patients were HLA-B27
positive. All patients gave informed consent and ethical
approval was obtained (Multicentre Research Ethics
Committee 98/5/23). Genotyping involved restriction frag-
ment length polymorphism (RFLP) analysis of PCR prod-
ucts performed under standard conditions. Primers
(forward 50-GCATCCATGGCTAATGTGCR and reverse
50-GTTGTGGGAAAGCCGAACTA) amplified a 370-bp
product that, in the presence of the G allele, was digested
to 214 and 156bp products by HphI. Genotype and allele
frequencies in AS cases and controls were compared
using the CochraneArmitage test of trend and the
chi-squared test, respectively. This study had 80%
power under a log-additive model to detect an odds
ratio (OR) of 1.3 with a population risk of AS of 0.04%
and a risk allele frequency of 46% (frequency in our con-
trols) at a significance level of 0.05. There were no signifi-
cant differences between allele or genotype frequencies in
AS cases and controls at rs2248374 (Table 1).
Additionally, due to the potential functional significance
of homozygosity at the minor G allele (i.e. no functional
ERAP2 protein), we also compared the frequency of GG
homozygotes in AS cases and controls, but these proved
almost identical again (Table 1).
The association between ERAP1 and AS is the second
only to HLA-B27, but formal testing for additional associ-
ation with the neighbouring gene, ERAP2, had not been
previously undertaken. A study of familial AS that typed
one marker within ERAP2 reported that an ERAP1/ERAP2
haplotype was over-represented in affected family
members [5]. However, such studies are frequently con-
founded by linkage disequilibrium effects. If genetic vari-
ation at ERAP2 were to play a role in susceptibility to
AS, then a dramatic loss-of-function variant, such as
rs2248374, would appear to be a prime candidate for
the ‘causal variant’ at this locus. However, we have now
excluded any significant effect arising from this important
functional ERAP2 variant. Nonetheless, the possibility of
other associations between ERAP2 and AS has not been
excluded by this study. This could be done only by sys-
tematic mapping of the gene with tagging SNPs in a very
large sample after controlling for the significant linkage
disequilibrium between ERAP1 and ERAP2 would this
TABLE 1 Genotypes, minor allele frequency (MAF), OR, 95% CI and P-value for the ERAP2 SNP rs2248374
Patients and controls
Genotype counts
MAF OR (95% CI) P-value AA AG GG
AS cases (n¼470) 125 245 100 0.47 1.07 (0.77, 1.14) 0.46
Controls (n¼420) 128 201 91 0.46
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. Despite its major functional effect on ERAP2 ex-
pression, rs2248374 shows no association with AS.
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Relapsing polychondritis-associated meningitis
and encephalitis: response to infliximab
SIR, Relapsing polychondritis (RPC) is an uncommon sys-
temic inflammatory disorder of unknown origin. A minority
of patients with RPC develop neurological involvement
(3%) [1]. The prognosis of patients with RPC complicated
by meningoencephalitis (ME) is poor. The reported
mortality of RPC-associated meningitis is 12% (3 out of
25 patients), and that of patients with RPC-associated
encephalitis is 36.4% (4 out of 11 patients) [28].
Therapy with infliximab has been effective in several
cases of resistant RPC. Nevertheless, the effects of
anti-TNF-a therapy on RPC-associated meningitis and
encephalitis have not previously been described. We
report a patient with RPC and recurrent episodes of ME
refractory to therapy with high-dose glucocorticoids and
CYC, who had a satisfactory and long-lasting response to
therapy with infliximab.
A 57-year-old male who immigrated 8 years ago from
Ecuador presented with fever (up to 39 C), severe head-
ache and two generalized seizures. During the previous
4 years, he had had one episode of erythema nodosum,
and several episodes of symmetrical polyarthritis (hands
and wrists), auricular chondritis, painful red eyes and
dizziness, with the diagnoses of scleritis, cochlear dys-
function and neural deafness.
On admission, he was febrile (38.5 C) and confused
with positive meningeal signs and a normal CT scan of
the brain. Lumbar puncture (LP) disclosed 700 cells/ml,
98% lymphocytes, glucose 50mg/dl and proteins
75mg/dl. Cerebrospinal fluid (CSF) studies were negative
for bacteria, virus, fungi and parasites or abnormal cells.
Peripheral blood leucocytosis (20 10
9/ml, 90% neutro-
phils) and elevated acute-phase reactant proteins were
observed. Kidney and liver function, ANAs, ANCAs, RF,
urinanalysis and serological tests for HIV, hepatitis B virus,
hepatitis C virus, CMV, EBV, treponema, rickettsias,
borrelia, coxiella, brucella and echinococcus were all
normal or negative. MRI of the brain showed small T2
gadolinium-enhanced lesions in the periventricular white
matter of both cerebral hemispheres (Fig. 1b). The patient
improved with high-dose i.v. methylprednisolone and was
discharged.
During the following 20 months, he had seven admis-
sions for ME with negative CSF studies. These episodes
occurred while the patient was not taking any medications
previously associated with ME, including non-steroidal
anti-inflammatory agents. Although these episodes of
ME improved with high-dose i.v. glucocorticoids plus
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